Addario Lung Cancer Medical Institute - ALCMI

02/26/2026

Whoa! Mayo Clinic researchers led by Henrique Borges da Silva, Ph.D., have uncovered how lung tumors exploit regulatory T cells via P2RX7 to evade immunotherapy.

Mayo Clinic researchers identify how P2RX7-driven regulatory T cells promote immunotherapy resistance in lung cancer, pointing to a potential new treatment strategy.

02/25/2026

Pranshu Mohindra, MD, MMM, from University Hospitals Cleveland Medical Center Inc., presents a compelling case for expanding the use of hypofractionated radiotherapy in lung cancer treatment.

Pranshu Mohindra, MD, outlined considerations for optimizing the use of hypofractionated radiation for patients with lung cancer.

02/24/2026

Congratulations to Johnson & Johnson! The FDA has approved RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy with monthly subcutaneous dosing for first-line EGFR-mutated advanced NSCLC.

Monthly dosing reduces treatment visits while maintaining established safety and efficacy1,2 Builds on RYBREVANT FASPRO™ FDA approval to deliver the simplest and fastest combination regimen for EGFR+ non-small cell lung cancer1,3-6

02/19/2026

The NRG ONCOLOGY/Alliance Healthcare LU005 trial, led by Kristin Higgins, MD, shows that concurrent and adjuvant atezolizumab added to chemoradiation does not improve overall survival in limited-stage small cell lung cancer, as published in the Journal of Clinical Oncology.

Data from the phase 3 LU005 trial found no OS benefit and high immune-related toxicity with concurrent/adjuvant atezolizumab and chemoradiation in LS-SCLC.

02/18/2026

New news on COVID-19 and lung cancer. Imperial College London researchers have uncovered epithelial injury biomarkers that predict residual lung abnormalities in COVID-19 survivors, as detailed in a new eBioMedicine study led by Iain Stewart, Ph.D.

Injury and scarring markers are seen in association with RLA on follow-up CT following recovery from COVID-19.

02/17/2026

A new review from Debanjan Bhattacharya, PhD, Benjamin Roman, and Sanjana Reddy in Cancer Gene Therapy provides a clear picture of how next‑generation KRASG12C inhibitors are shaping the future of intracranial disease control in NSCLC.

Non-small cell lung cancer (NSCLC) frequently metastasizes to the brain in approximately 20–40% of cases. Mutations in the Kirsten rat sarcoma viral oncogene homologue (KRAS) are common in NSCLC, with the KRASG12C variant accounting for approximately 40% of KRAS-mutant cases. Up to 40% of NSCLC pa...

02/16/2026

The FDA has granted RMAT designation to KB707, an inhaled replication-defective HSV-1 immunotherapy from Krystal Biotech, Inc., supported by early efficacy signals from the phase 1/2 KYANITE-1 study.

Early data from the KYANITE-1 study support the RMAT designation for KB707 as a treatment for those with advanced or metastatic NSCLC.

02/15/2026

The NORTHSTAR trial has established a significant EGFR-specific benefit for local consolidative therapy in stage IV EGFR-mutant NSCLC, demonstrating an 8-month improvement in progression-free survival when added to osimertinib.

02/14/2026

At ALCMI, our hearts are in the research. This Valentine’s Day, we celebrate the incredible patients, families, and researchers who inspire us every day.

02/13/2026

KRAS allele identity dictates the fundamental biology of lung cancer, as William Hai-Cheng Huang MD, and colleagues demonstrate that G12C and G12D mutations diverge in oncogenic potency, immune engagement, and relapse kinetics.

KRAS G12D and G12C produce lung tumors with distinct microenvironmental and growth features that influence progression and survival.

02/10/2026

Metastatic lung cancer and adenocarcinoma histology are among the strongest predictors of acute ischemic stroke, according to a new American Heart Association scientific statement that defines cancer-related stroke as a distinct, high-risk clinical entity.

About 10% to 15% of patients with ischemic stroke have a history of cancer, half of whom have active malignancy at the time of stroke. With improved cancer treatments extending patient survival, the coprevalence of these diseases has increased steadily since 2000. This has sparked considerable growt...

02/09/2026

Save the date! Summit Therapeutics, Inc.s’ PD-1/VEGF bispecific ivonescimab now has an FDA decision date of November 14 for EGFR-mutant, locally advanced or metastatic non-squamous NSCLC.

The FDA is currently reviewing Summit's PD-1/VEGF bispecific as part of a chemotherapy combo for the treatment of locally advanced or metastatic non-squamous non-small cell lung cancer.